Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference
January 07, 2016 17:56 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare...
Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results
December 16, 2015 16:57 ET
|
Mesoblast Limited
Materially Strengthened Cash Reserves First Royalties From TEMCELL Product Sales Expected In Q1 2016 Resources Prioritized On Tier 1 Product Candidates Cash Managed To Extend Runway And Achieve...
Mesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015
December 15, 2015 19:50 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced it will report financial results for the quarter ended 30 September...
Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease
November 27, 2015 06:00 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received...
Mesoblast Investor Update
November 23, 2015 00:07 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Nov. 23, 2015 (GLOBE NEWSWIRE) -- The Mesoblast Board and management are committed to delivering the Tier 1 product milestones as set out in the recent F-1...